Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 16;29(3):593–604. doi: 10.1038/s41591-022-02189-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 8 — a, Pretherapy tumor PD-L1 IHC membranous expression (%) in malignant cells from responders and nonresponders treated with Nivo+CT and Ipi+Nivo+CT by MPR status (MPR vs. no MPR, n = 9 vs. n = 13). Data is presented as the median with minima, lower and upper quartiles, and maxima using violin plots. Individual data points are shown; the dashed line shows the median value, and dotted lines show lower quartile and upper quartile values; the top and bottom of the violin plots indicate the maxima and minima. Two-sided P value is from Wilcoxon’s rank-sum test. b, c, Examples of hematoxylin and eosin (H&E) micrographs (left panels) of pretherapy tumors from patients with MPR in Nivo+CT (b) and in Ipi+Nivo+CT (c) arms with pretherapy PD-L1 expression (right and top panel) or without PD-L1 expression (right and bottom panel) in malignant cells. Experiments and scorings related to the presented micrographs were conducted once. d-g, Quantification of CD3+CD8+ T cells (panel 1) (d), CD3+PD-1+ T cells (panel 1) (e), CD3+CD8+CD45RO+ T cells (panel 2) (f), and CD3+CD8+GZB+ T cells (panel 2) (g) densities (no. per mm²) by mIF staining in paired pretherapy and post-therapy tumor samples in Nivo+CT (n = 11) and Ipi+Nivo+CT (n = 11) groups. Two-sided P value is from Wilcoxon’s signed-rank test. h-k, Examples of micrographs of mIF staining of pretherapy and post-therapy CD3+CD8+ T cells (panel 2 and 1) (h), CD3+PD-1+ T cells (panel 1) (i), CD3+CD8+CD45RO+ T cells (panel 2) (j), and CD3+CD8+GZB+ T cells (panel 2) (k) in tumor samples in Nivo+CT and Ipi+Nivo+CT arms. Experiments and scoring related the presented micrographs were conducted once. The green filled and empty circles depict data from MPR and no MPR, respectively, in Nivo+CT patients, and the red filled and empty circles depict data from MPR and no MPR, respectively, in Ipi+Nivo+CT patients. Nivo, nivolumab; Ipi, ipilimumab; CT, chemotherapy; MPR, major pathologic response. Source data for panels a, d-g is provided as Source Data file.

Source data